0
0
New Delhi, May 19, 2025:
India’s pharmaceutical industry has cemented its position as a global powerhouse, ranking 3rd in the world by volume and 14th by value. According to recent reports and expert analysis from India Ratings, the sector is poised for robust growth, with projections of a 7.8% year-on-year increase in April 2025, fueled by strong demand and a steady stream of innovative products.
A Global Leader in Affordable Medicines
India now supplies a staggering 20% of the world’s medicines, making it the largest provider of affordable generic drugs. The industry’s turnover soared to ₹4,17,345 crore in 2023-24, maintaining an impressive annual growth rate of over 10% for the past five years.
“For the common man, this means more medicines at lower prices, better healthcare, and jobs in factories and labs across the country. From small towns to big cities, India’s pharma growth is creating opportunities and saving lives,” a government official highlighted.
Vaccines: Saving Lives Worldwide
India’s role as a vaccine supplier is equally significant. The country provides 55-60% of UNICEF’s vaccines and fulfills 99% of the World Health Organization’s demand for the DPT vaccine (Diphtheria, Whooping Cough, and Tetanus). It also supplies 52% of the global BCG vaccine (used against tuberculosis) and 45% of measles vaccines. Indian vaccines are credited with saving millions of lives across continents, from Africa to the Americas.
Job Creation and Foreign Investment
The sector’s growth has led to substantial job creation, employing a wide range of professionals from factory workers to scientists. In 2023-24 alone, foreign investors injected ₹12,822 crore into the industry, drawn by India’s strong potential and government-friendly policies. The government allows 100% foreign investment in medical devices and greenfield pharma projects, making India a prime destination for global companies.
Government Initiatives Driving Growth
Several government schemes have played a pivotal role in this success:
-
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP): With 15,479 Jan Aushadhi Kendras, this initiative offers generic medicines at prices up to 80% lower than branded alternatives. For example, a heart medicine that once cost ₹500 is now available for ₹100.
-
Production Linked Incentive (PLI) Schemes:
-
₹15,000 crore supports 55 projects to produce high-end drugs for cancer and diabetes within India.
-
₹6,940 crore focuses on making raw materials like Penicillin G domestically, reducing import dependence.
-
₹3,420 crore is allocated for boosting production of medical devices such as MRI machines and heart implants.
-
-
Promotion of Bulk Drug Parks: ₹3,000 crore is being invested to establish mega hubs in Gujarat, Himachal Pradesh, and Andhra Pradesh, aiming to make medicines cheaper and more accessible.
-
Strengthening of Pharmaceuticals Industry (SPI) Scheme: With ₹500 crore, this scheme funds research and lab upgrades, helping Indian companies stay competitive globally.
Looking Ahead
With these concerted efforts, India’s pharmaceutical sector is not only making medicines more affordable for its own citizens but is also playing a crucial role in global healthcare. The industry’s focus on innovation, affordability, and quality continues to drive its upward trajectory.
Disclaimer:
This article is based on information sourced from The Sentinel Assam and related expert commentary. While every effort has been made to ensure accuracy, readers are advised to consult official government releases and industry reports for the most current and comprehensive data.
